September 13, 2017

UConn spin-off gets stem cell patent for autoimmune diseases

ImStem Biotechnology Inc. and the University of Connecticut today announced that a joint patent was recently issued for human embryonic stem cell technology being used by ImStem to develop therapies for autoimmune diseases, with an initial focus on Multiple Sclerosis.

The company, spun out of the UConn Stem Cell Core Lab, was formed to commercialize the technologies developed by Dr. Ren He Xu, the former director of the UConn Stem Cell Core, and his then postdoc, Dr. Xiaofang Wang. Wang now leads the company as its chief technology officer with CEO Dr. Michael Men.

In 2010, Xu was one of few researchers to derive new stem cell lines when he announced that four UConn lines had been approved for use in federally funded research and added to the National Stem Cell Registry by the National Institutes of Health, according UConn. Both ImStem and its enabling research had been funded by the state of Connecticut Stem Cell Grant program.

Today, ImStem operates through private capital raised by its founders and is located at the UConn Technology Incubation Program (TIP) in Farmington.

While ImStem has proven its T-MSC cell therapy protects mice from MS, it is currently working with the FDA on necessary clearances to begin clinical trials next year and has completed FDA required experiments. ImStem believes its technology might address diseases beyond MS, including the company's next target, Inflammatory Bowel Disease.

Free E-Newsletters

Sign up now for our daily and weekly
e-newsletters! Click Here

Today's Poll Does your company make use of Internet of Things technology?<>
Most Popular on Facebook
Copyright 2017 New England Business Media